Lipoxin B4 regulates human monocyte/neutrophil adherence and motility

Design of stable lipoxin B4 analogs with increased biologic activity

Jane F. Maddox, Sean P. Colgan, Clary B. Clish, Nicos A. Petasis, Valery V. Fokin, Charles N. Serhan

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Lipoxins are biologically active products of arachidonic acid that are formed via cell-cell interactions, particularly those involving leukocytes. Lipoxin A4 and lipoxin B4 (LXB4), within similar concentration ranges, each inhibit human neutrophil, activate monocyte adherence and motility, and are rapidly converted by initial dehydrogenation to other inactive metabolites by human monocytes. Here, we exposed LXB4 to isolated recombinant 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) and found that it was a good substrate for the enzyme (K(m)=6.9 μM); we identified the major product as 5-oxo-LXB4 via physical methods including liquid chromatography/tandem mass spectrometry. This is the first evidence of 15- PGDH converting a substrate hydroxyl group at a position other than the ω-6 carbon. Based on these observations, several LXB4 analogs were designed and prepared by total organic synthesis to test as stable mimetics: 5(S)-methyl- LXB4-me, 5(R)methyl-LXB4-me, and 15-epi-LXB4-me (the aspirin-triggered form of LXB4). Both 5(S)-methyl-LXB4-me and 5(R)-methyl-LXB4-me were resistant to rapid conversion. In addition, actions of the stable analogs were evaluated separately with human monocytic cells and neutrophils, and 5(S)-methyl-LXB4-me was more potent (nM range) than LXB4 for both cell types. In contrast, 5(R)-methyl-LXB4-me was potent in inhibiting neutrophil transmigration across endothelial monolayers, but did not stimulate monocyte adherence. These results indicate that LXB4 analogs can be designed to resist rapid transformation and retain bioactivity with both monocytes and neutrophils. Moreover, they suggest that LXB4 stable analogs are useful tools to selectively evaluate the modes of actions of LXB4 with different tissues.

Original languageEnglish
Pages (from-to)487-494
Number of pages8
JournalFASEB Journal
Volume12
Issue number6
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

monocytes
neutrophils
bioactive properties
Monocytes
Neutrophils
cells
aspirin
enzyme substrates
arachidonic acid
liquid chromatography
prostaglandins
leukocytes
mechanism of action
metabolites
synthesis
lipoxin B4
carbon
15-hydroxyprostaglandin dehydrogenase
testing
Lipoxins

Keywords

  • Eicosanoids
  • Inflammation
  • Leukocytes
  • Lipid mediators

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Maddox, J. F., Colgan, S. P., Clish, C. B., Petasis, N. A., Fokin, V. V., & Serhan, C. N. (1998). Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: Design of stable lipoxin B4 analogs with increased biologic activity. FASEB Journal, 12(6), 487-494.

Lipoxin B4 regulates human monocyte/neutrophil adherence and motility : Design of stable lipoxin B4 analogs with increased biologic activity. / Maddox, Jane F.; Colgan, Sean P.; Clish, Clary B.; Petasis, Nicos A.; Fokin, Valery V.; Serhan, Charles N.

In: FASEB Journal, Vol. 12, No. 6, 1998, p. 487-494.

Research output: Contribution to journalArticle

Maddox, JF, Colgan, SP, Clish, CB, Petasis, NA, Fokin, VV & Serhan, CN 1998, 'Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: Design of stable lipoxin B4 analogs with increased biologic activity', FASEB Journal, vol. 12, no. 6, pp. 487-494.
Maddox, Jane F. ; Colgan, Sean P. ; Clish, Clary B. ; Petasis, Nicos A. ; Fokin, Valery V. ; Serhan, Charles N. / Lipoxin B4 regulates human monocyte/neutrophil adherence and motility : Design of stable lipoxin B4 analogs with increased biologic activity. In: FASEB Journal. 1998 ; Vol. 12, No. 6. pp. 487-494.
@article{50ef350ad2554a008eaede2c04f0e3dc,
title = "Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: Design of stable lipoxin B4 analogs with increased biologic activity",
abstract = "Lipoxins are biologically active products of arachidonic acid that are formed via cell-cell interactions, particularly those involving leukocytes. Lipoxin A4 and lipoxin B4 (LXB4), within similar concentration ranges, each inhibit human neutrophil, activate monocyte adherence and motility, and are rapidly converted by initial dehydrogenation to other inactive metabolites by human monocytes. Here, we exposed LXB4 to isolated recombinant 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) and found that it was a good substrate for the enzyme (K(m)=6.9 μM); we identified the major product as 5-oxo-LXB4 via physical methods including liquid chromatography/tandem mass spectrometry. This is the first evidence of 15- PGDH converting a substrate hydroxyl group at a position other than the ω-6 carbon. Based on these observations, several LXB4 analogs were designed and prepared by total organic synthesis to test as stable mimetics: 5(S)-methyl- LXB4-me, 5(R)methyl-LXB4-me, and 15-epi-LXB4-me (the aspirin-triggered form of LXB4). Both 5(S)-methyl-LXB4-me and 5(R)-methyl-LXB4-me were resistant to rapid conversion. In addition, actions of the stable analogs were evaluated separately with human monocytic cells and neutrophils, and 5(S)-methyl-LXB4-me was more potent (nM range) than LXB4 for both cell types. In contrast, 5(R)-methyl-LXB4-me was potent in inhibiting neutrophil transmigration across endothelial monolayers, but did not stimulate monocyte adherence. These results indicate that LXB4 analogs can be designed to resist rapid transformation and retain bioactivity with both monocytes and neutrophils. Moreover, they suggest that LXB4 stable analogs are useful tools to selectively evaluate the modes of actions of LXB4 with different tissues.",
keywords = "Eicosanoids, Inflammation, Leukocytes, Lipid mediators",
author = "Maddox, {Jane F.} and Colgan, {Sean P.} and Clish, {Clary B.} and Petasis, {Nicos A.} and Fokin, {Valery V.} and Serhan, {Charles N.}",
year = "1998",
language = "English",
volume = "12",
pages = "487--494",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "6",

}

TY - JOUR

T1 - Lipoxin B4 regulates human monocyte/neutrophil adherence and motility

T2 - Design of stable lipoxin B4 analogs with increased biologic activity

AU - Maddox, Jane F.

AU - Colgan, Sean P.

AU - Clish, Clary B.

AU - Petasis, Nicos A.

AU - Fokin, Valery V.

AU - Serhan, Charles N.

PY - 1998

Y1 - 1998

N2 - Lipoxins are biologically active products of arachidonic acid that are formed via cell-cell interactions, particularly those involving leukocytes. Lipoxin A4 and lipoxin B4 (LXB4), within similar concentration ranges, each inhibit human neutrophil, activate monocyte adherence and motility, and are rapidly converted by initial dehydrogenation to other inactive metabolites by human monocytes. Here, we exposed LXB4 to isolated recombinant 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) and found that it was a good substrate for the enzyme (K(m)=6.9 μM); we identified the major product as 5-oxo-LXB4 via physical methods including liquid chromatography/tandem mass spectrometry. This is the first evidence of 15- PGDH converting a substrate hydroxyl group at a position other than the ω-6 carbon. Based on these observations, several LXB4 analogs were designed and prepared by total organic synthesis to test as stable mimetics: 5(S)-methyl- LXB4-me, 5(R)methyl-LXB4-me, and 15-epi-LXB4-me (the aspirin-triggered form of LXB4). Both 5(S)-methyl-LXB4-me and 5(R)-methyl-LXB4-me were resistant to rapid conversion. In addition, actions of the stable analogs were evaluated separately with human monocytic cells and neutrophils, and 5(S)-methyl-LXB4-me was more potent (nM range) than LXB4 for both cell types. In contrast, 5(R)-methyl-LXB4-me was potent in inhibiting neutrophil transmigration across endothelial monolayers, but did not stimulate monocyte adherence. These results indicate that LXB4 analogs can be designed to resist rapid transformation and retain bioactivity with both monocytes and neutrophils. Moreover, they suggest that LXB4 stable analogs are useful tools to selectively evaluate the modes of actions of LXB4 with different tissues.

AB - Lipoxins are biologically active products of arachidonic acid that are formed via cell-cell interactions, particularly those involving leukocytes. Lipoxin A4 and lipoxin B4 (LXB4), within similar concentration ranges, each inhibit human neutrophil, activate monocyte adherence and motility, and are rapidly converted by initial dehydrogenation to other inactive metabolites by human monocytes. Here, we exposed LXB4 to isolated recombinant 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) and found that it was a good substrate for the enzyme (K(m)=6.9 μM); we identified the major product as 5-oxo-LXB4 via physical methods including liquid chromatography/tandem mass spectrometry. This is the first evidence of 15- PGDH converting a substrate hydroxyl group at a position other than the ω-6 carbon. Based on these observations, several LXB4 analogs were designed and prepared by total organic synthesis to test as stable mimetics: 5(S)-methyl- LXB4-me, 5(R)methyl-LXB4-me, and 15-epi-LXB4-me (the aspirin-triggered form of LXB4). Both 5(S)-methyl-LXB4-me and 5(R)-methyl-LXB4-me were resistant to rapid conversion. In addition, actions of the stable analogs were evaluated separately with human monocytic cells and neutrophils, and 5(S)-methyl-LXB4-me was more potent (nM range) than LXB4 for both cell types. In contrast, 5(R)-methyl-LXB4-me was potent in inhibiting neutrophil transmigration across endothelial monolayers, but did not stimulate monocyte adherence. These results indicate that LXB4 analogs can be designed to resist rapid transformation and retain bioactivity with both monocytes and neutrophils. Moreover, they suggest that LXB4 stable analogs are useful tools to selectively evaluate the modes of actions of LXB4 with different tissues.

KW - Eicosanoids

KW - Inflammation

KW - Leukocytes

KW - Lipid mediators

UR - http://www.scopus.com/inward/record.url?scp=0032037672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032037672&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 487

EP - 494

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 6

ER -